Patient-Oriented Evidence That Matters

Terbinafine and Itraconazole Are Most Effective for Toenail Onychomycosis


Am Fam Physician. 2020 Oct 15;102(8):online.

Clinical Question

What is the preferred monotherapy for the treatment of toenail onychomycosis?

Bottom Line

For toenail onychomycosis, continuous terbinafine (Lamisil), 250 mg, and continuous itraconazole (Sporanox), 200 mg, for 12 to 24 weeks are the preferred therapies. (Level of Evidence = 1a−)


Network meta-analyses can include direct comparisons (drug A vs. drug B in individual trials) and indirect comparisons (comparing drug A with drug C by linking studies of A vs. B and B vs. C). The researchers performed an appropriate search, and, of the 10,845 studies initially identified, 75 met the inclusion criteria, but only 26 reports of 31 clinical trials provided outcome data regarding cure rates or adverse events that could be used in the analysis. The included studies had a total of 8,136 patients and reported eight treatment regimens, including some with the same drug given continuously or in a pulsed fashion (i.e., daily for one week of a month). Most studies treated patients for 12 to 24 weeks, and the study drugs included ciclopirox 8% solution (Loprox), efinaconazole 10% solution (Jublia), fluconazole (Diflucan), itraconazole, terbinafine, and tavaborole 5% solution (Kerydin). The researchers used conventional methods for data abstraction, quality assessment, and analysis.

Of the 31 trials, only five were judged to be at overall low risk of bias. Most studies failed to describe randomization procedures or allocation concealment, 52% failed to mask participants, and 64% failed to mask outcome assessors. Itraconazole, 200 mg, and terbinafine, 250 mg, were most effective, based on placebo-controlled trials. Continuous regimens were more effective than pulsed regimens. This is consistent with the results based on direct and indirect comparisons. Continuous terbinafine and continuous itraconazole were most likely to be effective for mycologic cure. Adverse events did not differ much among the drugs; itraconazole was the safest.

Study design: Meta-analysis (ra

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, editor-in-chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.



Want to use this article elsewhere? Get Permissions

More in AFP

Editor's Collections

Related Content

More in Pubmed


Oct 2021

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article